Hormonal contraceptives and the length of their use are not independent risk factors for high-risk HPV infections or high-grade CIN

• Autor(a) principal: Longatto Filho, Adhemar
• Data de Publicação: 2011
• Outros Autores: Hammes, L. Serpa, Sarian, L., Roteli-Martins, C., Derchain, S., Eržen, M., Branca, M., Tatti, S., Naud, P., Matos, J. C., Gontijo, R., Maeda, Marina Yoshiê Sakamoto, Lima, Temístocles, Costa, S., Syrjänen, S., Syrjänen, K.
• Tipo de documento: Artigo
• Idioma: eng
• Título da fonte: Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
• Texto Completo: http://hdl.handle.net/1822/25632
• topic: Hormonal contraceptives; Cervical intraepithelial lesions; High-risk human papillomavirus; Cohort study; Science & Technology

AIMS: To evaluate the role of hormonal contraceptives as a risk factor of high-risk human papillomavirus (HR-HPV), cervical intraepithelial lesions (CIN) and cervical cancer in our multi-center population-based LAMS (Latin American Screening) study. METHODS: A cohort study with >12,000 women from Brazil and Argentina using logistic regression to analyze the covariates of hormonal contraception (HOC - oral, injections, patches, implants, vaginal ring and progesterone intrauterine system) use followed by multivariate modeling for predictors of HR-HPV and CIN2+. RESULTS: HR-HPV infection was a consistent risk factor of high-grade CIN in all three groups of women. The length of HOC use was not significantly related to high-grade squamous intraepithelial lesions (HSIL)+ Pap (p = 0.069), LSIL+ Pap (p = 0.781) or ASCUS+ (p = 0.231). The same was true with the length of HOC use and histology CIN3+ (p = 0.115) and CIN2+ (p = 0.515). Frequently, HOC users have previously shown more HPV-related lesions, as well as lower HPV prevalence if they were current smokers. But HOC use and time of usage were not independent risk factors of either HR-HPV infection or high-grade CIN using multiple logistic regressions. CONCLUSIONS: No evidence was found for an association between the use of HOC with an increased risk for HR-HPV infection or high-grade CIN in this cohort.